Section Sub-head
Header
Sub-head
Header
Sub-head
-
Recor Medical Statement on CMS National Coverage Analysis of Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced that the Centers for Medicare and Medicaid Services (CMS) have begun a National Coverage Analysis (NCA) of Renal Denervation (RDN), a medical device-based treatment for hypertension.
-
Recor Medical Announces CMS Grant of Transitional Pass-Through (TPT) Payment for Recor’s Paradise Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced U.S. Centers for Medicare & Medicaid Services (CMS) have granted the company’s Paradise® Ultrasound Renal Denervation system a Transitional Pass-through (TPT) payment. The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal…
-
Recor Medical Endorses European Society of Cardiology’s New Guidelines for Management of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) have endorsed the updated recommendations for the management of hypertension by the European Society of Cardiology (ESC), which were presented at the ESC Congress on Friday, August 30, 2024. The new guidelines, “2024 ESC Guidelines for the management of elevated…
-
Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) greatly appreciate the American Heart Association (AHA) for providing a well-considered statement on the application of renal denervation (RDN) as a therapy option to treat high blood pressure. The AHA scientific statement was based on a balanced literature review…
-
CMS Approves Additional Payment for Recor Medical’s Paradise Ultrasound Renal Denervation System in Hospital Inpatient Cases
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) announced today that the Centers for Medicare and Medicaid Services (CMS) published the Final Rule for Fiscal Year 2025 Hospital Inpatient Prospective Payment Systems (IPPS), approving a New Technology Add-On Payment (NTAP) for the Paradise™ Ultrasound Renal Denervation (uRDN)…
-
First Patients Treated in Recor Medical’s Global Paradise System US Post Approval Study (US GPS) for the Treatment of Uncontrolled Hypertension with Ultrasound Renal Denervation
Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the first patients in the US have been treated in Recor Medical’s Global Paradise® System US Post Approval Study (US GPS), a real-world study gathering data on the long-term safety and effectiveness of ultrasound renal denervation (uRDN). Dr. Antonio…